Effects of clomiphene citrate on endometrial morphology.

Evaluation of endometrial pinopod concentrations changes during the ovulation induction by Clomiphene citrate plus Estradiol valerate and Clomiphene citrate plus Progesterone comparison with Clomiphene citrate alone among infertile women.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015011920408N3

Enrollment

Unknown

Registered

2016-10-05

Start date

2016-10-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Diseases of the genitourinary system. Condition 2: Diseases of the genitourinary system. Condition 3: Diseases of the genitourinary system. Female infertility of uterine origin Female infertility of other origin Hyperstimulation of ovaries

Interventions

Intervention 1: Intervention 1: Clomiphene citrate (Tab, 50 mg, oral, three times a day, on days 5-9 of menstrual cycles, Aburaihan company, Iran) plus estradiol valerate (Tab 2 mg, oral, twice daily

Treatment - Drugs

Intervention 3: Clomiphene citrate (Tab, 50 mg, oral, three times a day, on days 5-9 of menstrual cycles, Aburaihan company, Iran) and endometrial biopsy (Novak curette, Bonyan Atieh Darman Company, I

Intervention 1: Clomiphene citrate (Tab, 50 mg, oral, three times a day, on days 5-9 of menstrual cycles, Aburaihan company, Iran) plus estradiol valerate (Tab 2 mg, oral, twice daily for 5 days on da

Intervention 2: Clomiphene (Tab, 50 mg, oral, three times a day, on days 5-9 of menstrual cycles, Aburaihan company, Iran) plus medroxy progesterone acetate (Tab 5 mg, oral, twise daily, from day 14 u

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Infertile women have 35 years old and younger; regular menstrual cycles, resistant to clomiphene citrate; no previous history of in vitro fertilization; and no other causes of infertility. Exclusion criteria: Women aged over 35 years; irregular menstrual cycles; prior good response to clomiphene.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Endometrial concentrations of pinopod. Timepoint: On 21 of cycles. Method of measurement: Questionnaire.	—

Secondary

Measure	Time frame
Estrogen concentrations. Timepoint: On day 21 of menstrual cycles. Method of measurement: Estrogen laboratory kit.;Progesterone concentrations. Timepoint: On 21 of menstrual cycles. Method of measurement: Progesterone laboratory kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Zamaniyan

Reproductive and Infertility Health Research Center, Shahid Beheshti University of Medical Sciences,

marziehzamaniyan@gmail.com+98 21 2271 2234

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026